ADVERTISEMENT — Advertise With Biotech Networks
No Picture
Industry News

Early Surveillance with L-Dex® Reduces Incidence, Severity & Cost of Breast Cancer-Related Lymphedema, ImpediMed Reports Publication in American Cancer Society Journal

BRISBANE, Australia & CARLSBAD, Calif.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/Lymphedema?src=hash" target="_blank"gt;#Lymphedemalt;/agt;–L-Dex Reduces Incidence, Severity & Cost of Breast Cancer-Related Ly… […]

No Picture
Industry News

Apexian Pharmaceuticals Presents Findings at ASH Meeting Demonstrating APX3330 Impact on Inflammation and Leukemia?in Preclinical Models

INDIANAPOLIS–(BUSINESS WIRE)–Apexian Pharmaceuticals is shedding light on the question of how pre-leukemic cells transform into full-blown leukemia. Genetic mutations by themselves are rarely enough to flip the switch. Inflammation also plays a role…. […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
Industry News

Pfizer adds 100 to cancer research center in La Jolla

Pfizer is adding 100 jobs to its oncology research center in La Jolla, increasing employment to more than 900. Pfizer is transferring those positions from its site in South San Francisco. The move, announced Monday, was made to simplify the structu… […]


ADVERTISEMENT — Advertise With Biotech Networks

ADVERTISEMENT — Advertise With Biotech Networks
No Picture
Industry News

Human Longevity’s valuation reportedly plummets

Human Longevity, a La Jolla developer of health and disease-prevention technologies, appears to be in a cash crunch, according to a Friday article in the Wall Street Journal. The company, co-founded by genomics pioneer J. Craig Venter, is raising u… […]

No Picture
Industry News

Liver drug developer Jecure acquired by Genentech

Jecure Therapeutics, a San Diego company targeting inflammatory liver diseases, said Tuesday it has agreed to be purchased by Genentech. The purchase price wasn?t disclosed. Privately held Jecure was founded in 2015 with financing from Versant Vent… […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
Industry News

Genetically modified humans arrive. Now what?

For good or ill, perhaps both, humanity?s newfound power to change the genome of our species has been put to use. Chinese scientist Jiankui He genetically engineered human embryos, resulting in the first-ever births of genetically altered babies. T… […]

No Picture
Industry News

ResMed to buy lung health company for $225 million

San Diego?s ResMed, a seller of equipment and software for sleep apnea and related conditions, says it has agreed to buy Propeller Health for $225 million. Madison, Wis.-based Propeller Health provides devices and software for people with chronic o… […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
Industry News

ViaCyte raises $80 million for diabetes therapy

Diabetes therapy developer ViaCyte has raised $80 million, its largest financing to date, ?the San Diego biomedical company said Wednesday. ViaCyte will use the money to advance its stem cell-derived therapies, said Paul Laikind, president and CEO … […]

No Picture
Industry News

HIV drugs may help people with Alzheimer’s and Down syndrome, says new hypothesis on Alzheimer’s origins

A major new study on Alzheimer?s disease provides previously unknown evidence of how the brain-robbing illness may originate. Moreover, it proposes that certain HIV drugs called reverse transcriptase inhibitors could immediately be repurposed for A… […]

No Picture
Industry News

Agbiotech Cibus files for $100 million IPO

San Diego agricultural biotech company Cibus said Monday it has filed for an IPO of up to $100 million. It’s the second IPO filing for a local biotech in a week. The company says it uses advanced gene-editing technology to favorably alter plant gen… […]


ADVERTISEMENT — Advertise With Biotech Networks

ADVERTISEMENT — Advertise With Biotech Networks
No Picture
Industry News

Cancer drug developer Synthorx files for $100 million IPO

Synthorx, a La Jolla biotech developing cancer therapies from partly synthetic life, is seeking $100 million in an initial public offering. The Scripps Research spinoff made the filing with the Securities and Exchange Commission on Tuesday. It seek… […]

No Picture
Industry News

EpiPen rival from San Diego’s Adamis nears market

Challenging the popular but pricey EpiPen, San Diego?s Adamis Pharmaceuticals is readying its own emergency allergy medication for sale. Called Symjepi, the product is a pre-filled syringe of epinephrine, used to counteract life-threatening allergi… […]


ADVERTISEMENT — Advertise With Biotech Networks